Ensysce Biosciences, Inc. ENSC
were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from
PharmacoFore, Inc. to Signature Therapeutics Inc. ("Signature"). In December 2015, Signature merged with and into
Ensysce Biosciences, Inc. ("Former Ensysce"). In June 2021, Former Ensysce merged with and into Leisure Acquisition
Corporation ("LACQ"). As part of the transaction, LACQ changed its name to "Ensysce Biosciences, Inc."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M | $3.9M | — | — | — |
| R&D | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M | $4.4M | — | — | — |
| SG&A | $4.9M | $4.7M | $5.4M | $6.9M | $18.7M | $1.2M | — | — | — |
| Total operating expenses | $15.3M | $11.9M | $12.9M | $26.7M | $23.4M | $5.5M | $3.3M | $1.6M | — |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M | -$1.6M | -$3.3M | -$959.2K | — |
| Interest expense | $18.8K | $1.3M | $353.9K | $109.5K | $1.3M | $995.5K | — | — | — |
| Pre-tax income | — | — | — | — | — | $4.6M | -$512.1K | $2.7M | — |
| Income tax | — | — | — | — | — | $244.5K | $555.2K | $553.9K | — |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$24.2M | -$29.1M | -$160.9K | -$1.1M | $2.1M | — |
| EPS, basic | -3.98 | -11.45 | -70.40 | -139.42 | -29.64 | 0.00 | — | — | — |
| EPS, diluted | -3.98 | -11.45 | -70.40 | -139.42 | -1.48 | 0.00 | -0.63 | -0.21 | — |
| Shares, diluted (wtd. avg.) | $2.6M | $697.7K | $150.9K | $179.9K | $1.0M | $16.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M | $194.2K | — | — | — |
| Total current assets | $7.2M | $5.3M | $2.3M | $5.3M | $15.7M | $347.9K | $1.2M | $1.9M | $2.3M |
| Property, plant and equipment | $124.1K | — | — | — | — | $151 | — | — | — |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M | $351.8K | $196.5M | $204.8M | $202.4M |
| Accounts payable | $3.3M | $1.4M | $1.9M | $2.9M | $301.1K | $1.7M | $2.8M | $429.2K | $112.0K |
| Total current liabilities | $4.6M | $2.2M | $3.3M | $9.5M | $16.5M | $7.0M | $2.8M | $437.9K | $156.2K |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M | $7.0M | $13.2M | $12.7M | $11.8M |
| Retained earnings | -$139.7M | -$129.5M | -$121.6M | -$110.9M | -$85.8M | -$56.0M | $2.5M | -$233.8K | -$5.2K |
| Total equity | $3.2M | $3.7M | -$651.3K | -$4.0M | -$8.2M | -$6.7M | -$6.7M | $5.0M | $5.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M | -$1.2M | -$1.4M | -$1.2M | — |
| Depreciation and amortisation | $6.5K | $0 | $0 | $0 | $151 | $201 | — | — | — |
| Stock-based compensation | $177.1K | $110.7K | $879.2K | $1.1M | $121.8K | $178.7K | — | — | — |
| Capital expenditure | $123.6K | — | — | — | — | — | — | — | — |
| Investing cash flow | -$123.6K | — | — | $4.5K | — | $183.4M | $11.9M | $838.6K | — |
| Financing cash flow | $8.7M | $9.9M | $8.8M | $8.8M | $20.3M | $1.1M | -$11.0M | -$32.0K | — |
| Buybacks | — | — | — | — | — | $184.8M | $11.6M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013633.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |